术后放疗对完全切除的病理性IIIA(N2)期非小细胞肺癌患者有效吗?高风险人群应考虑接受
本研究基于前瞻性随机试验(NCT02974426)中高危局部区域复发(LRR)风险、完全切除的IIIA(N2)期非小细胞肺癌(NSCLC)患者,以倾向性评分匹配(PSM)与非PORT回顾性队列比较。结果显示PORT改善LRFS、DFS和OS,DMFS无差异。作者认为高危LRR患者可从PORT获益。
要点
- 高危LRR、完全切除的IIIA(N2)期NSCLC患者接受PORT后3年LRFS为77.6%,非PORT队列为57.3%。
- PORT组3年OS为83.0%,非PORT队列为60.7%,差异有统计学意义。
- PORT组3年DFS为35.2%,非PORT队列为28.6%,DMFS两组无差异。
核心结论
- PORT可提高高危LRR、完全切除的IIIA(N2)期NSCLC患者的局部控制、DFS和OS。
- 作者认为未来研究应利用多维数据确定更精确的PORT获益亚组,并经前瞻性试验验证这些发现。
研究设计与样本
- 前瞻性随机试验(NCT02974426)自2016年7月开始,探索高危LRR、完全切除的IIIA(N2)期NSCLC患者PORT的最佳时机。
- 通过预后指数(PI)模型识别高危LRR患者,随机分配至PORT-first或PORT-last治疗。
- 该试验所有患者构成PORT队列;高危LRR但未接受PORT的患者选自回顾性队列,构成非PORT队列。
- 采用倾向性评分匹配(PSM)分析比较OS、DFS、LRFS和DMFS。
- 2016年至2022年共132例患者入组试验,中位随访49.3个月;122例(92%)接受了计划PORT。
主要发现
- 对132例意向性治疗患者与非PORT队列(n=307)进行PSM分析,得到130对匹配。
- PORT改善LRFS:3年LRFS为77.6% vs 57.3%(p=0.00014)。
- PORT改善DFS:3年DFS为35.2% vs 28.6%(p=0.038)。
- PORT改善OS:3年OS为83.0% vs 60.7%(p=0.00017)。
- DMFS两组无差异(p=0.17)。
关键数值与推荐
- PORT队列3年OS率为83.2%,3年DFS率为35.0%。
- PSM分析中PORT组3年LRFS为77.6%,非PORT队列为57.3%(p=0.00014)。
- PSM分析中PORT组3年DFS为35.2%,非PORT队列为28.6%(p=0.038)。
- PSM分析中PORT组3年OS为83.0%,非PORT队列为60.7%(p=0.00017)。
- DMFS比较p=0.17。
临床怎么用
- 作者认为PORT可提高高危LRR、完全切除的IIIA(N2)期NSCLC患者的局部控制、DFS和OS。
- 原文未据此给出具体临床推荐。
局限性
- 未来研究应利用多维数据确定更精确的PORT获益亚组,并经前瞻性试验验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We aimed to assess the benefits of postoperative radiotherapy (PORT) in completely resected patients with pathologic stage IIIA(N2) non-small cell lung cancer (NSCLC) with a high risk of locoregional recurrence (LRR). MATERIALS AND METHODS: A prospective, randomized trial was conducted starting in July 2016 to explore the optimal timing of PORT in high-LRR-risk patients with completely resected IIIA(N2) NSCLC (NCT02974426). Patients were identified as high-LRR-risk patients via the prognostic index (PI) model and were randomly assigned to PORT-first or PORT-last treatment. To evaluate PORT for high-LRR-risk patients, all patients in this trial constituted the PORT cohort, whereas high-LRR-risk patients without PORT were selected from a retrospective cohort as the non-PORT cohort. Propensity score-matched (PSM) analyses were conducted to compare overall survival (OS), disease-free survival (DFS), locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS). RESULTS: Between 2016 and 2022, 132 patients were included in the trial, with a median follow-up of 49.3 months. The 3-year OS rate was 83.2 %, and the 3-year DFS rate was 35.0 %. Among these patients, 122 patients (92 %) received planned PORT. For 132 intention-to-treat patients, PSM analysis with the non-PORT cohort (n = 307) resulted in 130 matched pairs. The results revealed that PORT improved LRFS (3-year LRFS, 77.6 % vs. 57.3 %; p = 0.00014), DFS (3-year DFS, 35.2 % vs. 28.6 %; p = 0.038), and OS (3-year OS, 83.0 % vs. 60.7 %; p = 0.00017), with no difference in DMFS (p = 0.17). CONCLUSION: PORT could increase local control, DFS, and OS in high-LRR-risk patients with completely resected IIIA(N2) NSCLC. Future research should utilize multidimensional data to pinpoint more precise subgroups benefiting from PORT, with prospective trials validating these findings.
引用
- Zhang SX, Zhang CC, Hou RP, et al. Is postoperative radiotherapy effective in patients with completely resected pathologic stage IIIA(N2) non-small cell lung cancer? High-risk populations should consider it. Clin Transl Radiat Oncol. 2024. PMID: 39634198. doi:10.1016/j.ctro.2024.100889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。